Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate




Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

• AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry

TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) — Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”). The engagement will deploy Kala Bio’s purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.

Strategic Rationale

The engagement of the Kala’s Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. By deploying custom purpose-built AI agents trained by Younet engineers in collaboration with Kala and under private cloud LLM infrastructure (supplied by Kala), Red Light intends to accelerate and enhance research planning, scenario simulation, and protocol optimization processes associated with advancing PEX010 through its clinical development program.

PEX010 is Filament’s patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others. These indications represent areas of growing clinical and commercial momentum, with programs from Compass Pathways and AtaiBeckley also advancing psilocybin and psychedelic candidates toward late-stage regulatory milestones, and Johnson & Johnson’s Spravato continuing to demonstrate strong commercial traction in treatment-resistant depression.

The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder.

Researgency.ai is an agentic AI platform developed by Younet.ai with exclusive worldwide distribution/development license owned by Kala Bio, designed to deploy secure, on-premises AI agents purpose-built for biotechnology and pharmaceutical R&D workflows. The platform enables autonomous research loops capable of generating, simulating, and optimizing study scenarios at scale — compressing timelines and expanding the number of viable options considered before execution. The approach mirrors a broader industry shift toward purpose-built AI infrastructure for drug development, an area where NVIDIA and Eli Lilly have also committed significant resources through dedicated computing partnerships and in-house platforms.

Management Commentary

“As we move to integrate Filament’s exceptional clinical assets and intellectual property, engaging Kala Bio’s Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation,” said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland. “PEX010 is already one of the most widely studied botanical psilocybin drug candidates in the world. By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010’s extensive clinical program.”

“Filament’s focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development,” said Ben Lightburn, Chief Executive Officer of Filament Health Corp. “With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio’s Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve.”

“Red Light’s decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address,” said Avi Minkowitz, Chief Executive Officer of Kala Bio. “Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference. We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world.”

About Researgency.ai

Researgency.ai is an agentic AI platform under worldwide distribution/development license by Kala Bio Inc. (NASDAQ: KALA) launched by Younet.ai, designed to bring autonomous research-agent workflows to biotechnology R&D planning. The platform deploys purpose-built AI agents that can simulate scenarios, optimize protocols, and support evidence-driven decisions in a secure, on-premises environment built for pharmaceutical-grade compliance. For more information, visit www.Researgency.ai.

About PEX010

PEX010 is a patented botanical psilocybin drug candidate developed by Filament Health Corp. PEX010 is formulated as a capsule for oral administration and is protected by Filament’s portfolio of 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations. PEX010 is currently supplied to more than 70 clinical research sites worldwide and is being studied in multiple Health Canada and FDA-authorized clinical trials across a range of mental health indications.

About Red Light Holland

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is a Toronto-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences. The Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands’ legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws. Red Light has entered into a definitive arrangement agreement to acquire Filament Health Corp., which is expected to expand the Company’s drug development platform with GMP manufacturing capabilities, comprehensive Health Canada licensing, FDA-authorized clinical programs, and a portfolio of 76 issued patents. For more information, visit www.RedLight.co.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates. 

About Kala Bio, Inc.

Kala Bio, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry. For more information, visit www.kalarx.com.

For additional information on Red Light Holland:

Todd Shapiro 
Chief Executive Officer & Director 
Tel: 647-204-7129 
Email: todd@redlight.co 
Website: www.RedLight.co

For additional information on Filament:

Benjamin Lightburn
Chief Executive Officer & Director 
Email: ben@filament.health
Website: www.filament.health

For additional information on Kala Bio, Inc.:

Kala Bio, Inc.
Avi Minkowitz
Chief Executive Officer
Email: am@kalarx.com
Website: www.kalarx.com
www.Researgency.ai

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian and United States securities legislation, including statements regarding the expected benefits and applications of the Researgency.ai platform in connection with PEX010 and Red Light’s drug development programs; the anticipated impact of AI-driven research tools on clinical development timelines and decision-making; the expected completion of Red Light’s acquisition of Filament; and the future development and commercialization of PEX010. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the ability to develop, deploy, and integrate new AI technologies; the performance and reliability of AI models and simulations; data availability and quality; cybersecurity and privacy considerations; the regulatory environment for psychedelic substances and AI-driven tools in Canada, the United States, and internationally; the ability to complete the acquisition of Filament on the anticipated terms and timeline; the ability to realize the anticipated benefits of the Filament transaction; the ability to retain key personnel; risks inherent in clinical drug development; and other risks described in Red Light’s and Kala Bio’s respective public filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Neither Red Light nor Kala Bio undertakes any obligation to update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland




VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland

— The lowered pricing structure is now available for 101.82 EUR per bottle at pharmacies throughout Finland

AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) — VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious medical conditions and life-limiting diseases, today announced the new price reduction of QSIVA® hard modified-release capsules phentermine/topiramate, is now in effect in Finland. The updated pricing reflects an average cost of 3.39 EUR per day, or considering the completer results on the top dose from the pivotal clinical trials, it is approximately 98 EUR per kilogram of weight loss. An individual’s results may vary.

“The price reduction of QSIVA is genuinely welcome. Too often, I see patients forced to stop a medication that is working for them simply because the cost is too high. Lowering the price is a step toward more equitable access to effective obesity care—regardless of income. Obesity is a chronic disease and, for many people, requires long-term treatment and follow-up. Medication can be an important and effective part of care, alongside lifestyle support. Just as importantly, patients benefit from structured, multidisciplinary follow-up so treatment can be individualized—choosing the right option, adjusting the dose when needed, and supporting sustainable health behaviours in the long run,” said Emilia Huvinen, Naistentautien ja synnytysten erikoislääkäri, LT.

According to the 2025 World Obesity Atlas, 22% of Finnish adults live with obesity, and 57% of adults have a high body mass index (BMI). Excess body weight is associated with an increased risk of serious health conditions, including cardiovascular disease, stroke, and diabetes, which are among the leading causes of mortality. Effective treatment options such as QSIVA can support patients in achieving and maintaining clinically meaningful weight loss, helping to improve long-term health outcomes and overall well-being.

“Obesity remains a significant public health challenge in Finland, affecting millions of people and increasing the risk of serious, chronic diseases,” said John Amos, Chief Executive Officer at VIVUS LLC. “With this price reduction now in effect, we aim to improve access to QSIVA and support healthcare professionals and patients in addressing obesity through evidence-based treatment options.”

In the Phase III CONQUER trial, a 56-week clinical study, QSIVA demonstrated that subjects assigned to treatment achieved 7.8 – 10.9 percent weight reduction (ITT analysis) and 7.6 – 10.9 cm reduction of waist circumference after 56 weeks of treatment. Subjects who were treated with QSIVA for the full 56-week study period (completer on drug analysis) achieved 9.6 – 14.4 percent weight reduction and 9.4 – 13.6cm reduction of waist circumference after completion of treatment. These clinical trials also demonstrated that phentermine/topiramate in combination with a weight-loss diet and exercise program resulted in statistically significant and clinically important reductions vs. placebo in weight and waist circumference, coupled with improvements in important risk markers indicative of weight-related comorbidities, such as systolic and diastolic BP, triglycerides, fasting glucose and progression towards type 2 diabetes. QSIVA is available in the mid and top dose strengths evaluated in the Phase III CONQUER trial along with 2 other dose strengths. Dose selection should be individualized and determined by the treating physician based on patient characteristics, treatment response, and tolerability, in accordance with the approved prescribing information.

About VIVUS
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit https://vivus.com/.

About QSIVA
QSIVA (the European brand name for QSYMIA) is approved in Sweden, Denmark, Finland, Iceland, and Poland. QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on reducing cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations, have not been established. For more information on QSIVA, please visit QSIVA.eu. The website is accessible for healthcare professionals only through registration.

Important Safety Information for QSIVA

QSIVA® hard modified-release capsules phentermine/topiramate is contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); in patients with hypersensitivity to sympathomimetic amines, to the active substances, or to any of the excipients in QSIVA.

QSIVA can cause foetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use highly effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should consult promptly with their doctor. The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, depression, constipation, and dry mouth.

Forward-Looking Statements

Important Information and Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and/or covered by the “Bespeaks Caution” doctrine applied by the courts under the antifraud provisions of the federal securities laws, and other applicable provisions of the federal securities laws. Such forward-looking statements are based on current expectations, management’s beliefs, and certain assumptions made by the Company’s management. These statements may be identified by the use of forward-looking words such as “will,” “shall,” “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “should,” “plan,” “likely,” “opportunity,” “estimated,” and “potential,” and/or the negative use of these words or other similar words. All forward-looking statements included in this document are based on the Company’s current expectations, and the Company assumes no obligation to update any such forward-looking statements except to the extent otherwise required by law.

Forward-looking information about QSIVA, including statements regarding its clinical efficacy, safety profile, the anticipated impact of the price reduction on patient access and commercial performance, and its role in long-term obesity management, involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied in this press release.

Risks related to QSIVA include the potential benefits of the price reduction on patient access and uptake, the impact of revised pricing strategies on revenue and commercial performance, the continued success of pharmacy partnerships across the Nordics and Poland, competitive developments in the weight management market including injectable medications, and whether QSIVA will continue to be commercially successful in approved markets.

General risks include the ability to successfully manage commercial programs across multiple international markets; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of QSIVA; supply chain challenges; and competitive developments in the obesity and weight management therapeutic area.

The above factors, risks, and uncertainties are difficult to predict, contain uncertainties that may materially affect actual results, and may be beyond the Company’s control. New factors, risks, and uncertainties emerge from time to time, and it is not possible for management to predict all such factors, risks, and uncertainties. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore any of these statements may prove to be inaccurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by the Company or any other person that the Company’s objectives and plans will be achieved. These forward-looking statements speak only as of the date such statements were made or any earlier date indicated, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in underlying assumptions, or otherwise, unless otherwise required by law. This announcement is made in accordance with applicable securities regulations including the EU Market Abuse Regulation.

Contacts

VIVUS BV
T: +31 20 262 0959

Media – FINN Partners
Julian Tyndale-Biscoe
julian.tyndale-biscoe@finnpartners.com
T: +44 20 7046 8280

Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice




Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice

• 43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice.
• Veterinarians are seen as the most trusted source of pet health advice.
• “Small acts of love. Big moments of life” campaign is launching on World Parasite Awareness Day to increase understanding of how a simple act such as preventing parasites can have a big impact on keeping our cats and dogs healthy. 

World Parasite Awareness Day, held annually on March 20, is an important reminder that parasites such as fleas, ticks and worms are among the most common health threats for pets around the world, yet they can easily be prevented.   

 A global survey among 6,500 pet owners¹ shows that, despite frequent exposure to parasites, there is a significant need for greater awareness, clearer guidance and education, and stronger preventative habits among pet owners worldwide. 27% state that they are only slightly familiar with parasite risks or not familiar at all, and a large majority of respondents (75%) said they would value clearer advice on prevention. At the same time, 43% report that their pet had already experienced a parasite infection, with one in five cases occurring within the last year. These findings expose a critical gap between experience and understanding and demonstrate the need for stronger awareness and more consistent preventative action.

In the United States alone, more than 1.2 million dogs are estimated to be heartworm-positive². In Europe, the same disease has spread to new countries, while in parts of Latin America, Africa, and Asia, heartworm prevalence remains high due to regional conditions. Among external parasites, ticks are commonly found in pets worldwide. For instance, a recent survey in Italy showed that more than 47% of dogs could be infested³, while in a similar study across Southeast Asia up to 67% of owned dogs were found with at least one tick⁴. These blood-feeding parasites can transmit severe and in some cases life‑threatening diseases such as Lyme borreliosis (causing joint pain and in some cases kidney damage), babesiosis (a protozoan infection that destroys red blood cells) or ehrlichiosis (a bacterial infection that leads to fever and bleeding tendencies).   

Beyond causing discomfort and illness in pets, some parasites can also infest or spread infections to people. As parasites show up in more places due to warmer temperatures and increased travel, prevention has never been more relevant.  

Veterinarians can play a central role in assessing risk, recommending appropriate protection and supporting responsible care. They remain the most trusted source of pet health information, with 70% of pet owners identifying them as their primary reference for guidance. Because parasite risk varies depending on location, season and lifestyle, tailored advice, regular monitoring and responsible use of preventative solutions are essential to protecting pets and people.  

Boehringer Ingelheim, a global leader in animal health, is marking World Parasite Awareness Day with the launch of “Small acts of love. Big moments of life”, a global campaign aiming to raise awareness about how parasites can easily be prevented. “Parasite prevention is a simple yet meaningful way for pet owners to show how they care for the animals they love, but our survey shows that awareness does not always translate into consistent action,” said Claire Fowler, Head of Global Strategic Marketing for Animal Health at Boehringer Ingelheim. “Through this campaign, we want to encourage pet owners to see prevention as one of the small acts of care that help protect their pets and allow them to enjoy more happy and healthy moments together.”   

As a company dedicated to advancing preventative care, Boehringer Ingelheim continues to invest in research, collaborate closely with veterinarians and support educational initiatives that empower pet owners to make informed decisions. Launched around World Parasite Awareness Day at the start of spring in the Northern Hemisphere, its awareness campaign coincides with a time when parasite activity begins to rise in many regions. By encouraging simple habits of care that help protect the health of pets and strengthen the bond they share with their owners, the campaign puts consumer insights into action.

¹Pet owner survey: The survey was conducted among 6,500 pet owners across the UK, the US, France, Germany, Turkey, China, Japan, Mexico and Brazil. The interviews were conducted online by Sapio Research in January 2026 using an email invitation and an online survey.   

²American Veterinary Medical Association (AVMA). Heartworm incidence climbs despite preventive efforts. Published October 08, 2024. https://www.avma.org/news/heartworm-incidence-climbs-despite-preventive-efforts  

³Maurelli, M.P., Pepe, P., Colombo, L. et al. A national survey of Ixodidae ticks on privately owned dogs in Italy. Parasites Vectors 11, 420 (2018). https://doi.org/10.1186/s13071-018-2994-2  

⁴Colella V, Nguyen VL, Tan DY, Lu N, Fang F, Zhijuan Y, et al. Zoonotic Vectorborne Pathogens and Ectoparasites of Dogs and Cats in Eastern and Southeast Asia. Emerg Infect Dis. 2020;26(6):1221-1233. https://doi.org/10.3201/eid2606.191832  

About Boehringer Ingelheim 

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.   

About Boehringer Ingelheim – Animal Health business  

Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at boehringer-ingelheim.com/animal-health. For more information, visit www.boehringer-ingelheim.com/animal-health.  

About World Parasite Awareness Day   

World Parasite Awareness Day is held each year on March 20 to highlight the risk that parasites pose to pets and the people around them. Fleas, ticks, worms, and other parasites can lead to discomfort, illness, and in some cases life-threatening disease in pets, while certain parasitic infections can also spread to people. The day brings together veterinary associations, animal health organizations, and other groups to promote awareness of parasites and the importance of prevention. It is coordinated through www.parasiteawarenessday.com. 

Peace through well-being: Orion and CMI – Martti Ahtisaari Peace Foundation announce partnership




Peace through well-being: Orion and CMI – Martti Ahtisaari Peace Foundation announce partnership

ORION CORPORATION
PRESS RELEASE
18 March 2026 at 10:00 EET
      

Peace through well-being: Orion and CMI – Martti Ahtisaari Peace Foundation announce partnership

Orion Corporation (“Orion Pharma”) and CMI – Martti Ahtisaari Peace Foundation (“CMI”) have entered a strategic content partnership for 2026. The partnership channels insights from CMI’s peace mediation experts, turning decades of peace process experience into clear and accessible content for a broad audience.

“At Orion Pharma, we believe that building health is building peace. We continue to strengthen resilient healthcare systems in Europe and beyond, with a strong focus on research and development, and our medicines reaching patients in more than a hundred countries. These are long-term commitments to health and, ultimately, investments in peace for future generations,” says Liisa Hurme, President & CEO of Orion Pharma.

The partnership aims to inspire public discussion about peacebuilding and emphasises that societal health and well-being is fundamental to lasting peace. Instead of focusing on peace only after crises emerge, the cooperation highlights peace as a long-term, everyday practice rooted in skills such as dialogue, mediation and trust.

“We share CMI’s ambition for a more stable, just and healthy future for all, and see the core tenets of peacebuilding as an important part of our work and the broader societal discussion around health. We’re proud to start this partnership with them,” Hurme adds.

Prescriptions for Peace

A central part of the partnership is a nine-part video series titled Prescriptions for Peace. Drawing on insights from CMI’s peace mediation experts, the series distils their experience into short and accessible videos. Each episode focuses on one key condition for sustainable peace, such as trust, dialogue, inclusion, ownership and compromise.

As with effective medical treatments, sustainable peace requires commitment, responsibility and long-term effort. The series encourages reflection rather than offering ready-made answers, presenting peace as a conscious choice and a continuous process. The concept of prescriptions is used metaphorically to refer to expert-informed guidance rather than quick fixes.

“Sustainable peace is about much more than just ending violence and getting to a deal. In mediation processes, we see how trust and dialogue gradually create the foundations for more stable societies. Through the Prescriptions for Peace series, we want to share some of these lessons from peace processes with a wider audience,” says Hanna Klinge, Deputy CEO of CMI.

Read more about the collaboration and watch the Prescriptions for Peace videos: prescriptionsforpeace.fi

About Orion Pharma

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

About CMI
CMI – Martti Ahtisaari Peace Foundation is an independent, non-profit Finnish organisation dedicated to advancing peace through conflict resolution, dialogue, and mediation. The organisation was founded 25 years ago by Nobel Peace Prize laureate President Martti Ahtisaari. CMI is one of the world’s leading peace mediation organisations and has been involved in more than 50 peace processes across the globe.

Orion Corporation
  
Contact person Orion:
Terhi Ormio, Vice President Communications

tel. +358 10 426 4646

Contact person CMI:
Kaisa Raitio, Head, Communications and Private Fundraising

tel. +358 50 338 92 60
                                         

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com 

UREVO Unveils CyberMega Across the DACH Region: The First Smart Treadmill Engineered for Marathon Training at Home




UREVO Unveils CyberMega Across the DACH Region: The First Smart Treadmill Engineered for Marathon Training at Home

BERLIN, March 18, 2026 (GLOBE NEWSWIRE) — As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the CyberMega Smart Treadmill across the DACH region on March 5th. Engineered for high-intensity endurance training, it delivers the uncompromising road feel of outdoor running while insulating training plans from unpredictable weather. The treadmill is available now on UREVO’s official German website and Amazon for €999.99.

Native AI Coaching and Localized Support

A key innovation is the integrated AI Smart Marathon Coach, now featuring full support for the German language. Available via the UREVO Wellness Hub app, it acts as a digital training director to bring race-day discipline home. It provides real-time audio guidance, including warm-up reminders, pacing alerts, split-time analysis, and course time-limit tracking, allowing runners to maintain a structured rhythm without the distraction of manually adjusting settings.

Professional Preparation at Your Own Pace

The CyberMega is built for comprehensive endurance development. Runners can select specific distances, from 5K to a full Marathon, following a structured flow that mirrors a real race. Every session is tracked with precision, syncing seamlessly with Apple Health and Google Fit for professional-grade progress tracking and accountability within a centralized ecosystem.

Instant Setup and Space Efficiency

The CyberMega features the one-touch SwiftFold™ system, requiring no installation and ready to use straight out of the box. The console and armrests fold down smoothly for easy, space-saving storage when not in use.

Elite Marathon Performance Metrics

• Elite 4.0 HP Brushless Motor: Powers speeds up to 20 km/h, unlocking elite marathon pacing so runners of all levels can push their limits and experience professional racing speeds at home.
• Acoustic Optimization: Whisper-quiet operation below 40 dB, perfect for noise-sensitive German apartment living.
• Intelligent Incline System: 12% smart incline that dynamically replicates outdoor topography and engages stabilizing muscles.
• Virtual Racing & Event Ranking: Run iconic global routes and receive an estimated overall ranking, benchmarking finish times against real-world marathon standards.

“We created the CyberMega for runners who demand professional training at home without compromising space or convenience,” says Davis, CEO of UREVO. “By combining premium hardware, intelligent software, and user-centric design, we’ve built a treadmill that embodies our philosophy: Achieve More with Less.”

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4708fa7-68ef-4f1a-be5b-93a7f9f68fce

CONTACT: Contact Person:
Vincent Wang
Email: marketing@urevo.com

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants




CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additional 7,075,471 shares of its common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on March 19, 2026, subject to customary closing conditions. All of the shares of common stock and pre-funded warrants are being sold by CytomX.

CytomX expects to use the net proceeds from this offering for the continued development of Varseta-M and other pipeline programs. CytomX expects to use any remaining net proceeds from this offering for capital expenditures, working capital and other general corporate purposes.

Jefferies, Piper Sandler, Cantor and Barclays are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as co-manager for the offering.

A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) on March 16, 2026, and automatically became effective upon filing. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on March 16, 2026. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, for free from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, or by telephone at (800) 747-3924, or by email at prospectus@psc.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About CytomX Therapeutics

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Bristol Myers Squibb, Regeneron and Moderna.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements contained in this press release, including those relating to the anticipated completion of the offering and the planned use of proceeds, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the company’s ability to complete the offering, general economic conditions and other risks identified from time to time in the reports the company files with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 16, 2026, and the prospectus supplement and accompanying prospectus related to the offering to be filed with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date hereof, and the company undertakes no obligation to update or revise any of the statements. The company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. All other trademarks are the properties of their respective owners.

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
Stephanie.Ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
Colleen.ketchum@precisionaq.com

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants




SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the
pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded warrant. Gross proceeds from the offering are expected to be approximately $85 million, before deducting underwriting discounts and commissions and offering expenses. SAB BIO has granted the underwriters a 30-day option to purchase up to an additional 3,311,688 shares of common stock on the same terms and conditions. All of the securities in the offering are to be sold by SAB BIO. The offering is expected to close on or about March 19, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds it receives from this offering, together with its existing cash, cash equivalents and marketable securities, primarily to fund the continued development of our clinical stage product candidate, SAB-142 through ongoing and planned clinical trials, as well as for related manufacturing, regulatory, and operational activities, and for working capital and general corporate purposes.

Jefferies, UBS Investment Bank, Citigroup, and Barclays are acting as joint book-running managers for the offering. Chardan is acting as lead manager. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.  

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (No. 333-292482) that was filed with the U.S. Securities and Exchange Commission (the SEC) on December 29, 2025, and declared effective on January 7, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at ol-prospectus-request@ubs.com; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; or Barclays Capital Inc. by calling (888) 603-5847, or by mail at Barclays c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

Forward-Looking Statements
Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs and the timing for completion of the public offering, and the use of proceeds and anticipated total gross proceeds from the public offering.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS
Investors:
Sheila Carlson
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

Blood Sugar Harmony Liquid Drops Ingredients Disclosed: Complete Details Revealed




Blood Sugar Harmony Liquid Drops Ingredients Disclosed: Complete Details Revealed

SugarHarmony Research has released ingredient reference materials outlining the compounds associated with Blood Sugar Harmony Liquid Drops, citing scientific references and ingredient context as part of its published documentation

Tallmadge, OH, March 17, 2026 (GLOBE NEWSWIRE) — Disclaimer: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any supplement. If you purchase through links in this content, a commission may be earned at no additional cost to you.

This release is based on company-provided materials and is not intended as an independent product review or third-party evaluation. In this context, “ingredients disclosed” and “complete details revealed” refer to the company’s publication of ingredient references and associated research citations through its official website documentation. Product details, pricing, and policies are presented as stated by the company and should be verified directly before any purchasing decision.

SugarHarmony Research has made available a set of ingredient reference materials associated with Blood Sugar Harmony Liquid Drops, listing a range of botanical compounds, amino acids, and metabolic support ingredients with corresponding scientific citations. The information, published through the company’s official website, summarizes how individual ingredients cited in connection with the formulation have appeared in published research.

For consumers researching Blood Sugar Harmony Liquid Drops, one of the most common starting questions is straightforward — what is actually in this formula, and what does the research say about those ingredients? The company’s published reference materials address those questions directly. The sections below summarize the ingredient categories, the research context the company has cited, and the key distinctions consumers should understand before making any purchasing decision.

The company’s reference section lists 32 scientific citations corresponding to individual ingredients. The sections below organize those cited ingredients by functional category and summarize the research context referenced by the company, including the distinction between ingredient-level research and finished-product evidence.

You can review the company’s full ingredient and product details directly: View the current Blood Sugar Harmony Liquid Drops offer (official SugarHarmony page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement, particularly if you are managing an existing health condition or taking prescription medications.

What Is Blood Sugar Harmony Liquid Drops?

Blood Sugar Harmony Liquid Drops — also referred to as Sugar Harmony Drops — is a liquid dietary supplement distributed by SugarHarmony Research, with payments processed through ClickBank as the authorized retailer. According to the company, the product is a plant-based wellness support formula in a liquid drop format designed for daily use. Each bottle contains 2 fluid ounces, which the product listing describes as a 30-day supply at the recommended serving size.

Marketplace listings associate the product with the brand name Syvor, while the official website operates under the SugarHarmony Research name. The company markets the formula as suitable for both men and women.

One important consideration for consumers evaluating this product: Sugar Harmony Drops is a dietary supplement. Under current federal regulations, dietary supplements are not required to receive FDA approval before being sold. The FDA does not evaluate supplement efficacy claims prior to market entry. The company’s own website includes the standard disclaimer that statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

This context helps clarify how the ingredient research cited by the company should be interpreted.

Consumers interested in a broader evaluation of Sugar Harmony Drops’ marketing claims, pricing structure, and refund policies may also find relevant context in a 2026 consumer evaluation of Sugar Harmony Drops claims and pricing.

Glucose Metabolism Research Compounds

According to the company’s reference materials, the following ingredients are cited in connection with Blood Sugar Harmony Liquid Drops. Published studies have examined these compounds individually for properties related to glucose metabolism and insulin sensitivity — and they represent some of the most extensively studied botanicals in this category.

Gymnema Sylvestre is a tropical plant with a long history in traditional Ayurvedic practice. Studies cited by the company include Baskaran et al. (Journal of Ethnopharmacology, 1990) and Al-Romaiyan et al. (Diabetes, Obesity and Metabolism, 2010), which examined Gymnema for potential effects on glucose uptake and pancreatic cell function. Study dosages and participant populations varied across these investigations, and outcomes depended on the specific research design.

Chromium Picolinate appears in the company’s citations through Anderson (Diabetes, 1997) and Vincent (Journal of the American College of Nutrition, 2003), which examined chromium’s potential role in insulin sensitivity and glucose regulation. This is one of the more widely studied trace minerals in the blood sugar supplement space, though findings have varied depending on dosage, study population, and duration.

Bitter Melon (Momordica charantia) is cited through Sridhar et al. (Journal of Alternative and Complementary Medicine, 2008), which examined its potential effects on blood glucose parameters in specific study populations. Bitter Melon has a long history in traditional medicine across several cultures.

Cinnamon Extract is referenced through Khan et al. (Diabetes Care, 2003), one of the most frequently cited studies in the blood sugar supplement category. This research examined cinnamon’s potential relationship to glucose regulation and insulin sensitivity, though the findings have been debated in subsequent research and should not be interpreted as conclusive.

These are ingredient-level findings from published studies on individual compounds — not clinical evaluations of Blood Sugar Harmony Liquid Drops as a finished formula. These individual findings do not mean the product replaces prescribed treatment. Consult your physician before beginning any supplement, especially if you take blood sugar medications.

Metabolic Support and Energy Compounds

The company’s reference materials also cite several ingredients studied for broader metabolic support and energy metabolism properties at the individual compound level.

Green Tea Catechins are cited through Nagao et al. (American Journal of Clinical Nutrition, 2005), which examined potential effects on blood glucose levels and metabolic health markers. Green tea catechins are among the most widely researched botanical compounds in the metabolic wellness space and appear across many products in this category.

Guarana is referenced through Espinola et al. (Brazilian Journal of Medical and Biological Research, 1997), which studied its potential impact on glucose regulation and energy metabolism. Guarana naturally contains caffeine, which may be relevant for consumers sensitive to stimulants — a consideration worth discussing with a healthcare provider.

Forskolin (Coleus Forskohlii Extract) appears in the company’s citations through Seamon et al. (Trends in Pharmacological Sciences, 1981) and Godard et al. (Obesity Research, 2005), which examined its potential role in metabolic processes including glucose regulation.

Capsaicin is cited through Kang et al. (Journal of Agricultural and Food Chemistry, 2007) and Dasgupta et al. (Frontiers in Endocrinology, 2019), which examined potential effects on blood sugar parameters and related metabolic pathways.

These are ingredient-level research findings. Blood Sugar Harmony Liquid Drops as a finished product has not been clinically studied. Individual ingredient dosages per serving are not disclosed in the company’s publicly available labeling, which means these study dosages cannot be directly compared to what the formula delivers per serving.

Adaptogenic and General Wellness Compounds

According to the company’s published documentation, the formula also references several adaptogenic and general wellness ingredients that have been studied individually for health-related properties, including research touching on metabolic parameters.

Astragalus Membranaceus is among the most frequently cited ingredients in the company’s reference section, with three separate studies listed — Li et al. (2017), Cheng et al. (2012), and Wu et al. (2018) — examining its potential effects on insulin resistance and glucose metabolism. This botanical has a long history in traditional Chinese medicine and appears across multiple metabolic wellness formulations.

Korean Ginseng and Panax Ginseng are cited through Reay et al. (British Journal of Clinical Pharmacology, 2005), Attele et al. (Diabetes Care, 2002), and Reeds et al. (Current Opinion in Clinical Nutrition & Metabolic Care, 2013). Published studies have examined ginseng varieties for potential effects on blood glucose management and insulin sensitivity, with varying results depending on the specific ginseng variety, dosage, and study design.

Ashwagandha is referenced through Andallu et al. (Journal of Clinical Biochemistry and Nutrition, 2010), which examined its potential impact on blood glucose levels. While Ashwagandha is more commonly associated with stress adaptation research, it has been studied in metabolic contexts as well.

Maca Root and Eleuthero (Siberian Ginseng) round out the adaptogenic category, cited through Oshima et al. (2006) and Cicero et al. (2004) respectively, each examining potential effects on glucose homeostasis and blood glucose levels.

These are individual study findings cited by the company and should not be interpreted as guarantees of specific outcomes. Always consult a healthcare professional before adding any supplement to your routine, and do not change or stop medications without medical guidance.

Amino Acids and Supporting Compounds

The company’s reference section also cites published research on several amino acids and neurologically active compounds studied for various metabolic-related properties.

GABA (Gamma-Aminobutyric Acid) is cited through Adeghate et al. (Endocrine Reviews, 2008), which examined its potential role in insulin secretion and glucose homeostasis. GABA is primarily known as an inhibitory neurotransmitter, with its metabolic research representing a secondary area of investigation.

L-Carnitine is referenced through Ringseis et al. (American Journal of Clinical Nutrition, 2012) for potential connections to insulin sensitivity and energy metabolism. L-Arginine is cited through Lucotti et al. (Journal of Clinical Endocrinology & Metabolism, 2006) for potential effects on glucose tolerance. L-Tryptophan is cited through Markus et al. (Psychosomatic Medicine, 2005) for its potential role in insulin regulation, and Beta-Alanine through Derave et al. (Journal of Applied Physiology, 2007) for potential connections to insulin sensitivity and glucose uptake.

L-Tyrosine appears through Lücke et al. (Frontiers in Endocrinology, 2017), examining its relationship with insulin sensitivity and metabolic health — though this connection is less extensively studied than some of the botanical ingredients listed above.

These are ingredient-level research citations published by the company. Blood Sugar Harmony Liquid Drops as a finished product has not been clinically studied in any published trial located during the preparation of this release.

Antioxidant and Fruit-Based Compounds

The final category of ingredients cited in the company’s reference materials includes several antioxidant-rich and fruit-derived compounds studied for metabolic-related properties.

Grape Seed Extract is cited through Zern et al. (Journal of Nutrition, 2005), which examined potential antidiabetic properties related to insulin resistance. African Mango (Irvingia gabonensis) appears through Ngondi et al. (Lipids in Health and Disease, 2005), which studied potential effects on blood glucose and lipid profiles.

Acai Berry Anthocyanins are referenced through Kang et al. (Journal of Agricultural and Food Chemistry, 2011) for potential roles in blood glucose regulation. Citrus Flavonoids appear through Mulvihill et al. (Journal of Nutritional Biochemistry, 2016) examining their potential impact on glucose homeostasis. Raspberry Ketones are cited through Morimoto et al. (Planta Medica, 2005) for potential mechanisms of action related to glucose uptake and fat metabolism.

These are ingredient-level research findings cited by the company. Individual ingredient dosages per serving are not disclosed in publicly available labeling. You should not assume that the presence of an ingredient in a multi-compound formula means it is present at the dosage used in any particular study. Consult your physician before starting any new supplement.

The Dosage Transparency Question

One important consideration when evaluating Blood Sugar Harmony Liquid Drops — and one that applies broadly across the supplement category — is dosage transparency.

No clinical trials evaluating Blood Sugar Harmony Liquid Drops as a finished formula were identified in publicly available sources at the time of publication.

The company’s published materials list ingredient references and scientific citations; however, specific per-ingredient dosages are not disclosed in publicly available labeling reviewed for this release. That matters because the published studies cited on the product’s references page examined individual compounds at specific dosage ranges tailored to each study’s design.

Without knowing how much of each ingredient is in a single serving, healthcare professionals and consumers cannot directly compare the formula’s per-serving quantities to the dosing protocols used in the referenced research. This does not indicate the product has or lacks effect — it means the ingredient research citations cannot be mapped to serving-level amounts based on publicly available information.

Consumers seeking more specific dosage information may wish to contact the manufacturer directly at support@getsugarharmony.com. This is a reasonable question to consider before purchasing any supplement where individual ingredient amounts are not prominently listed.

Liquid Format Considerations

Blood Sugar Harmony Liquid Drops is marketed in a liquid drop format rather than the capsule or tablet format more commonly seen in this product category. According to the product listing, each bottle contains 2 fluid ounces providing 30 servings.

Liquid supplement formats are sometimes discussed in nutrition literature in terms of absorption characteristics compared to solid formats, though this varies by ingredient and formulation. The company markets the liquid format as part of the product’s appeal but doesn’t appear to make specific bioavailability claims comparing it to capsule-based alternatives. Any assumptions about liquid absorption advantages should be verified with a healthcare provider familiar with your situation.

Consumer Considerations When Reviewing Blood Sugar Harmony Liquid Drops

Consumers researching Blood Sugar Harmony Liquid Drops may wish to consider factors such as preferred supplement format, ingredient transparency, and whether the product’s cited ingredient profile aligns with discussions they have had with a qualified healthcare professional.

Supplement format preference. The liquid drop format may be relevant for consumers who prefer drops over capsules or tablets. Format preference is an individual consideration and does not indicate differences in product quality or effectiveness.

Ingredient-level research citations. The company’s 32 cited studies may be relevant for consumers who want to review the referenced research with a healthcare provider. These citations describe individual ingredient findings and can serve as a starting point for clinical conversations about whether specific compounds are appropriate for an individual’s health situation.

Dosage transparency. Limited public dosage transparency may be relevant for consumers or healthcare professionals seeking serving-level comparisons against published study protocols. As noted above, per-ingredient amounts do not appear to be publicly disclosed in available labeling.

Supplement category classification. Blood Sugar Harmony Liquid Drops is a dietary supplement, not a medication. Consumers managing diagnosed health conditions should evaluate this product category distinction with a qualified healthcare provider. Dietary supplements are not substitutes for prescribed medical treatment.

Lifestyle context. Published research consistently indicates that metabolic health outcomes are influenced by overall diet, physical activity, sleep, and other lifestyle factors. Consumers may wish to evaluate any supplement as one potential component within a broader wellness approach rather than a standalone intervention.

Questions consumers may wish to consider: Has the decision to add a blood sugar support supplement been discussed with a healthcare provider? Are there current medications that could interact with the cited ingredients? Is the difference between ingredient-level research and finished-product clinical evidence understood? These considerations help clarify whether the product’s profile aligns with an individual’s specific health situation.

Consumers interested in reviewing the full product details can do so here: View the current Blood Sugar Harmony Liquid Drops offer (official SugarHarmony page).

Pricing and Purchase Terms

According to the company’s website, Blood Sugar Harmony Liquid Drops is offered in multiple package configurations, with pricing, shipping terms, and related purchase conditions varying by selection. At the time of publication, the company listed multi-bottle options with different per-bottle pricing and shipping terms. Readers should verify the most current details directly on the official website before making any purchasing decision.

According to the company’s published policies, purchases may be eligible for a 60-day return period subject to the stated terms and return requirements. The refund process requires returning all bottles to the fulfillment address, with the buyer covering return shipping costs. Current refund terms, timeframes, and conditions should be verified on the official website or through ClickBank’s self-service portal.

The company’s published Terms of Service also describe a multi-step fulfillment process for certain package configurations. Consumers may wish to review that fulfillment structure carefully before making any purchasing decision.

What to Verify Before Purchasing

Understand the difference between ingredient research and product research. The studies cited by the company examined individual compounds under specific research conditions. They did not evaluate Blood Sugar Harmony Liquid Drops as a finished multi-ingredient liquid supplement. Understanding which type of evidence is being referenced helps establish realistic expectations.

Check whether individual ingredient dosages are disclosed. Full-disclosure labeling allows consumers and healthcare providers to compare serving contents against published research. When specific amounts are not listed, contacting the manufacturer directly is a reasonable step.

Read the terms of service and disclaimer pages. Important information about fulfillment procedures, refund requirements, and how the company characterizes expected results is often found in the fine print rather than on the main product page. Additional context on consumer considerations and company claims can be found in a separate analysis of SugarHarmony consumer concerns and claims.

Talk to a healthcare provider first. This is especially important for consumers taking prescription medications — particularly blood sugar medications, blood thinners, or diabetes medications — or managing an existing health condition. A qualified clinician familiar with the individual’s medical history is the most reliable resource for evaluating whether any supplement is appropriate. Do not change, adjust, or discontinue any medications or prescribed treatments without a physician’s guidance and approval.

Contact Information

For questions before or during the ordering process, according to the company’s website, SugarHarmony offers customer support:

Email: support@getsugarharmony.com
Return Address: 285 Northeast Ave, Tallmadge, OH 44278
Website: getsugarharmony.com
Payment Processor: Click Sales Inc., 1444 S. Entertainment Ave., Suite 410, Boise, ID 83709
Self-Service Billing Support: https://www.clkbank.com/
(US): +1 800-390-6035
(INT): +1 208-345-4245

View the current Blood Sugar Harmony Liquid Drops offer (official SugarHarmony page)

Disclaimers

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This content is educational and does not constitute medical advice. Blood Sugar Harmony Liquid Drops is a dietary supplement, not a medication. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting this or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, dietary habits, physical activity level, consistency of use, genetic factors, current medications, and other individual variables. Results are not guaranteed. The studies cited in this content examine individual ingredients under specific research conditions and do not represent clinical evaluations of Blood Sugar Harmony Liquid Drops as a finished product.

FTC Affiliate Disclosure: This content contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research citations provided by the company and publicly available information.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were accurate at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing and terms on the official SugarHarmony website before making your purchase.

Publisher Responsibility Disclaimer: The publisher of this content has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with SugarHarmony and their healthcare provider before making decisions.

Ingredient Interaction Warning: Some ingredients cited in the company’s reference materials — including Gymnema Sylvestre, Chromium Picolinate, Cinnamon, Bitter Melon, Ginseng, and others — have been individually studied for potential effects on blood glucose parameters. If you take blood sugar medications, insulin, blood thinners, diabetes medications, or any other prescription medications, consult your healthcare provider before starting any supplement containing these ingredients. Potential interactions between supplement ingredients and prescription medications should be evaluated by a qualified clinician familiar with your complete medical history.

CONTACT: Email: support@getsugarharmony.com

Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026




Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026

ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA, USA.

The data to be presented encompasses three of the Company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor Olverembatinib (HQP1351), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and PRC2/EED inhibitor APG-5918.

The AACR Annual Meeting 2026 is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

The four preclinical abstracts from Ascentage Pharma include:

Multitarget kinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma (EC)

• Abstract#: 4583
• Poster Session Category: Experimental and Molecular Therapeutics
• Session Title: Novel Antitumor Agents 2
• Time: Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PDT

Multikinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models

• Abstract#: 5875
• Poster Session Category: Experimental and Molecular Therapeutics
• Session Title: Tyrosine Kinase, Phosphatase, and Other Inhibitors
• Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PDT

FAK inhibition by APG-2449 enhances the antitumor activity of MAPK pathway blockade in BRAF V600E-mutant tumor models

• Abstract#: 1858
• Poster Session Category: Experimental and Molecular Therapeutics
• Session Title: Targeting Drug Resistance 1: Apoptosis and Autophagy
• Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM PDT

Embryonic ectoderm development (EED) inhibitor APG-5918 synergizes with topoisomerase I inhibitors in preclinical small-cell lung cancer (SCLC) models through epigenetic priming of chemosensitivity

• Abstract#: 4500
• Poster Session Category: Experimental and Molecular Therapeutics
• Session Title: Epigenetic Modulators 1
• Time: Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PDT

*Olverembatinib, APG-2449, and APG-5918 are currently under investigation and have not been approved by the U.S. FDA.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:

Yuly Chen, Senior Investor Relations Director
Ascentage Pharma
IR@ascentage.com
+86 512 85557777
+1 (301) 792-5658

Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282

Media Relations:

Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012

NatureGlyco Blood Support Claims Evaluated: The Proven Glyco Care Formula for Healthy Blood Sugar Support




NatureGlyco Blood Support Claims Evaluated: The Proven Glyco Care Formula for Healthy Blood Sugar Support

A 2026 company-issued informational report covering NatureGlyco’s product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching blood sugar support options

Wilmington, Delaware, March 17, 2026 (GLOBE NEWSWIRE) — This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new supplement. Affiliate Disclosure: If you purchase through links in this article, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented. In this report, phrases such as “claims evaluated,” “proven,” and similar product language refer strictly to NatureGlyco’s marketing or product-positioning language as presented in company materials and do not indicate that the finished product has been independently clinically proven effective.

NatureGlyco has prepared this 2026 informational report to provide readers with a consolidated summary of publicly available details about NatureGlyco Blood Support, including the company’s ingredient descriptions, package pricing, subscription structure, refund conditions, and customer-support contact information. According to the company, the purpose is to present these details in one place so readers can review them and verify current terms directly on the official NatureGlyco page.

This informational report is presented by NatureGlyco as the source company and summarizes product information drawn from the company’s public-facing materials and published terms.

All product details discussed below are stated as presented by NatureGlyco and should be verified directly on the official website before relying on any product information. Current product details, pricing, and terms can be confirmed directly here: View the current NatureGlyco Blood Support offer (official NatureGlyco page).

What NatureGlyco Blood Support Is

NatureGlyco Blood Support is a dietary supplement that the company markets primarily toward adults researching blood sugar support and related metabolic wellness topics. According to the brand’s official website, the product is positioned as a “triple action formula,” which the company connects to blood pressure, blood sugar, and weight-management support.

The company refers to its proprietary ingredient blend as the “Glyco Care Formula” — a combination of six plant-based and nutrient ingredients: White Mulberry Leaf, Juniper Berry, Biotin with Chromium, Berberine Extract, Bitter Melon, and Cinnamon Bark Powder.

An important note that applies throughout this report: NatureGlyco Blood Support is a dietary supplement, not a medication. The company’s own website includes the standard FDA disclaimer stating that the product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Any decision to use this product should involve consultation with a physician — particularly for anyone currently taking medications for blood sugar, blood pressure, or cholesterol.

NatureGlyco’s Glyco Care Formula: Ingredient Overview and Research Context

According to NatureGlyco, the formula highlights White Mulberry Leaf, Juniper Berry, Biotin with Chromium, Berberine Extract, Bitter Melon, and Cinnamon Bark Powder. The sections below summarize how these ingredients are described in company materials and note general ingredient-level research context often discussed in the blood sugar support supplement category.

Important: Any scientific discussion below relates to individual ingredients based on published research and should not be interpreted as proof that NatureGlyco Blood Support as a finished proprietary formula has been clinically studied or clinically proven effective. These individual findings do not mean NatureGlyco Blood Support replaces prescribed treatment.

White Mulberry Leaf

NatureGlyco’s materials describe White Mulberry Leaf as an ingredient shown to support healthy blood sugar levels. In the broader research landscape, White Mulberry Leaf (Morus alba) has been studied for its potential effects on blood sugar metabolism. Research published in peer-reviewed journals suggests that compounds in mulberry leaf — particularly 1-deoxynojirimycin (DNJ) — may help support healthy post-meal blood sugar responses by influencing how carbohydrates are processed in the digestive system. Some studies indicate that mulberry leaf extract may help support already-healthy blood sugar levels when used alongside a balanced diet, though results vary across study populations and dosages. Individual results with any supplement containing this ingredient will differ.

Berberine Extract

The company highlights Berberine Extract as a key ingredient for cholesterol and glucose support. In published research, berberine is among the most-studied natural compounds in the blood sugar support category. Multiple studies have explored berberine’s potential role in supporting healthy glucose metabolism and maintaining cholesterol levels already within normal range. Research has examined berberine’s interaction with metabolic pathways, with some studies suggesting it may influence how the body processes glucose at the cellular level. However, berberine can interact with certain prescription medications, including metformin and other blood sugar medications. Anyone taking prescription treatments should consult their physician before combining berberine-containing supplements with any prescribed medication. Do not change, adjust, or discontinue any medications without a physician’s guidance and approval.

Cinnamon Bark Powder

NatureGlyco’s materials reference Cinnamon Bark Powder for its role in supporting insulin levels. In the research context, cinnamon (Cinnamomum species) has a long history in traditional wellness practices and has been the subject of research examining its potential effects on blood sugar and insulin sensitivity. Some studies suggest that certain compounds in cinnamon may support the body’s natural insulin response, though research results have been mixed, and the type of cinnamon (Ceylon vs. Cassia) and dosage may significantly affect outcomes. This ingredient is generally well tolerated, but individuals taking blood sugar medications should consult their healthcare provider, as combined effects may require monitoring.

Bitter Melon

The company describes Bitter Melon as an ingredient for cholesterol balance. In published research, Bitter Melon (Momordica charantia) is widely used in traditional health practices across Asia, Africa, and Latin America. Published research has explored its potential role in supporting healthy blood sugar levels, with some studies examining compounds like charantin and polypeptide-p. While some research shows promising associations, results vary significantly based on the form, dosage, and study population. Bitter melon may also have mild gastrointestinal effects in some individuals. As with all ingredients discussed here, physician consultation is essential for anyone taking blood sugar or cholesterol medications.

Biotin with Chromium

NatureGlyco’s materials list Biotin and Chromium as ingredients supporting blood pressure levels and natural energy. In the broader research landscape, Biotin (Vitamin B7) and Chromium are essential micronutrients that play roles in normal metabolic processes. Chromium, particularly in its picolinate form, has been studied for its potential to support the body’s natural insulin function. Biotin participates in energy metabolism pathways. Research on supplemental chromium for blood sugar support has produced mixed results across different study populations. The National Institutes of Health notes that while chromium deficiency may affect blood sugar metabolism, the evidence for supplemental chromium in people with adequate dietary intake is less conclusive. Individual responses vary.

Juniper Berry

The company includes Juniper Berry as an ingredient for inflammation and weight management support. In the research context, Juniper Berry (Juniperus communis) has been used in traditional wellness practices and has been studied for potential antioxidant and anti-inflammatory properties. Some preliminary research has explored its possible effects on metabolic markers, though the body of clinical evidence is smaller compared to ingredients like berberine or cinnamon. Juniper berry is generally considered well tolerated in supplement form, but individuals who are pregnant, nursing, or taking medications should consult their healthcare provider before use.

These are individual ingredient findings based on published research. Individual results with NatureGlyco Blood Support will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. This supplement is not a replacement for prescribed medical treatment. Consult your physician before starting any new supplement.

The full ingredient list and company descriptions can be reviewed here: View the current NatureGlyco Blood Support offer (official NatureGlyco page).

NatureGlyco Pricing, Subscription Terms, and Refund Conditions

One of the most important things to review carefully before ordering any supplement is the full pricing structure, what happens after the first purchase, and what the refund process actually looks like. NatureGlyco’s published terms provide specific detail on all of these points.

According to the company’s terms of service, the pricing structure is as follows:

• 6-bottle package: $239.99 (+ free shipping) — approximately $39.99 per bottle
• 4-bottle package: $189.99 (+ free shipping) — approximately $47.49 per bottle
• 2-bottle package: $129.99 (+ free shipping) — approximately $64.99 per bottle

Recurring Monthly Subscription: According to NatureGlyco’s published terms (Section 2.3.1), this product is sold as a recurring monthly program. After the initial purchase, the company states that the same package price is charged again every 30 days until the customer contacts customer service to cancel. This is not a one-time purchase unless the subscription is actively cancelled. The company’s terms should be reviewed in full on the official website before ordering.

Refund Conditions: According to the company’s terms, NatureGlyco Blood Support offers a 60-day refund window from the date of purchase, subject to the following conditions as stated in the published terms:

• Customer service must be contacted before any refund arrangements are made
• The company states that the product must be returned to receive a full refund
• Per the company’s terms, all processed orders are subject to a $9.95 processing fee if the charge has settled
• All returns are subject to an $8.95 restocking fee per item if returned unopened, according to the published terms
• Refund requests are not accepted after 60 days from the purchase date, per the company’s stated policy

Current pricing, subscription terms, and refund conditions can be verified here: View the current NatureGlyco Blood Support offer (official NatureGlyco page).

Additional Published Company Terms

NatureGlyco’s terms of service reference several additional details worth reviewing before ordering:

Optional Add-On Product: The company’s terms mention an optional add-on product called NatureGlyco Daily Cleanse, priced at $59.99 (+ free shipping) for a 30-day supply. NatureGlyco states this add-on purchase is backed by a money-back guarantee.

Magazine Enrollment: Per the published terms, new customers may be enrolled in an exclusive monthly Magazine Series at a rate the company lists as $19.93. Consumers should verify current enrollment terms at checkout to understand all recurring charges that may apply.

Shipping: The company states that products ship within 24 hours of order and arrive within 5-7 business days. NatureGlyco notes that circumstances outside their control may occasionally cause delays.

Pregnancy/Medical Conditions: The company’s terms state that persons with a medical condition, who are pregnant, or who have reason to believe they may become pregnant should not order this product. The same terms note that refund requests will not be accepted for these reasons. The company requires that customers consult a physician prior to placing an order if they are unsure about whether they can take this product.

Consumer Verification Considerations

For anyone researching NatureGlyco Blood Support or any supplement in the blood sugar support category, the following points are worth reviewing before using any supplement:

Verify the ingredient list directly. NatureGlyco’s official website lists the formula’s ingredients. Confirming the specific ingredients and their forms helps consumers discuss the product with their healthcare provider before starting any new supplement.

Review the full subscription and billing terms. Because this product operates on a recurring 30-day billing cycle according to the company’s terms, understanding exactly how to cancel — and what fees may apply — is important before placing an initial order.

Understand the refund conditions in full. The 60-day refund window, processing fee, and restocking fee are all detailed in the company’s terms. Reviewing these before ordering helps set realistic expectations about the return process.

Consult a healthcare professional. This applies to any supplement, but is especially important for products in the blood sugar and metabolic health category. Several ingredients in this formula — particularly berberine, cinnamon, chromium, and bitter melon — may interact with prescription medications for blood sugar, blood pressure, cholesterol, or blood thinning. Do not change, adjust, or discontinue any medications without a physician’s guidance.

Understand the difference between ingredient research and finished-product evidence. The research discussed in this report relates to individual ingredients studied independently. NatureGlyco Blood Support as a finished proprietary formula has not been the subject of published clinical trials. This is common across the dietary supplement category but is an important distinction for consumers conducting due diligence.

Customer Support Information

According to the company’s website, NatureGlyco offers customer support through the following channels:

Phone: (877) 588-6435
Hours: 8AM – 8PM EST, Monday through Friday
Email: support@natureglycoblood.com

Readers who want to review NatureGlyco’s current product details, pricing terms, subscription structure, and customer-support information can do so here: View the current NatureGlyco Blood Support offer (official NatureGlyco page).

Company Information Summary

NatureGlyco Blood Support is a dietary supplement featuring what the company calls its “Glyco Care Formula” — a blend of six plant-based and nutrient ingredients marketed toward adults researching blood sugar support and related metabolic wellness topics. The company offers the product in three package tiers with a recurring monthly subscription model, a 60-day conditional refund window, and customer support available by phone and email during business hours.

Readers should distinguish between ingredient-level research and published clinical evidence on a finished proprietary formula. The most current information about any supplement’s ingredients, company practices, and terms should be reviewed before using any product.

NatureGlyco states that the purpose of this report is to make its published product information easier to review in one place. The company encourages readers to verify current terms directly on the official page and to consult a qualified healthcare professional before using any dietary supplement, especially for those who take prescription medications or are managing blood sugar concerns. 

Frequently Asked Questions

Is NatureGlyco Blood Support a medication?

No. According to the company, NatureGlyco Blood Support is a dietary supplement, not a medication. The company’s website includes the standard FDA disclaimer stating that the product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. It should not be used as a replacement for prescribed medical treatment.

Can NatureGlyco Blood Support be taken with prescription medications?

The company’s terms recommend consulting a physician before ordering if there is any uncertainty about whether the product is appropriate. Several ingredients in the formula — particularly berberine, cinnamon, chromium, and bitter melon — may interact with prescription medications. Anyone currently taking medications for blood sugar, blood pressure, cholesterol, or blood thinning should consult their healthcare provider before adding this or any supplement.

Is NatureGlyco Blood Support a one-time purchase?

According to the company’s published terms of service, this product is sold as a recurring monthly subscription. After the initial purchase, the same package price is charged again every 30 days until the customer contacts customer service to cancel. Review the full terms on the official website before ordering.

What is the refund policy?

According to the company’s terms, refunds are available within 60 days of purchase. Customer service must be contacted to initiate a return. Per the company’s stated policies, processed orders are subject to a $9.95 processing fee and returned items are subject to an $8.95 restocking fee per item. Verify current terms before ordering.

Has NatureGlyco Blood Support been clinically studied as a finished product?

Based on available information, NatureGlyco Blood Support as a finished proprietary formula has not been the subject of published clinical trials. The research discussed in this report relates to individual ingredients studied independently. This is common across the dietary supplement category. The company’s own website includes the standard FDA disclaimer noting that the product has not been evaluated by the FDA.

Disclaimers

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. NatureGlyco Blood Support is a dietary supplement, not a medication. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting NatureGlyco Blood Support or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Marketing Language Clarification: Phrases such as “claims evaluated,” “proven,” “Glyco Care Formula,” and similar product language used in this report refer strictly to NatureGlyco’s marketing or product-positioning language as presented in company materials. These phrases do not indicate that the finished product has been independently clinically proven effective. All product claims are attributed to the company’s published materials and should be verified directly on the official NatureGlyco website.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. No outcome can be guaranteed.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from NatureGlyco’s official website and published terms of service.

Pricing Disclaimer: All prices, subscription terms, and promotional offers mentioned were accurate based on publicly available information at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing, subscription terms, and refund conditions on the official NatureGlyco Blood Support website before relying on any product information.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with NatureGlyco and their healthcare provider before making decisions.

Ingredient Interaction Warning: Some ingredients in NatureGlyco Blood Support may interact with certain medications or health conditions. Berberine may interact with blood sugar medications, including metformin, and medications metabolized by the liver. Cinnamon may affect blood sugar levels in combination with diabetes medications. Chromium may enhance the effects of insulin or diabetes drugs. Bitter melon may have additive effects with blood sugar-lowering medications. Always consult your healthcare provider before starting any supplement, especially if you take blood thinners, blood pressure medications, diabetes medications, or have any chronic health conditions.

CONTACT: Phone: (877) 588-6435
Hours: 8AM – 8PM EST, Monday through Friday
Email: support@natureglycoblood.com